TCTristan William Clark

Tristan William Clark

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tristan William Clark has a total of 218 co-authors. Here are the top co-authors by number of shared publications:

  • Nathan James Brendish

    School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

    8 shared publications
  • Stephen Poole

    School of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom

    8 shared publications
  • Simon de Lusignan

    Affiliations Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom, Royal College of General Practitioners, London, United Kingdom

    7 shared publications
  • Uy Hoang

    Clinical Informatics and Health Outcomes Research Group, Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Rd, Oxford OX2 6GG, UK

    7 shared publications
  • Nathan J. Brendish

    NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Department of Infection, University Hospital Southampton NHS Foundation Trust, Southampton, UK; School of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK

    6 shared publications
  • Cecilia Okusi

    Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

    5 shared publications

Latest Publications

  • Open Access

    Host response profiling reveals heterogenous immune responses in hospitalised adults with respiratory viral detection

    by Alex R. Tanner, Bilge Eylem Dedeoglu, Nathan J. Brendish, Rebecca W.M. Wong, Irfaan Maan, Tristan W. Clark

  • Open Access

    The Impact of Point-of-Care Testing for Influenza on Antimicrobial Stewardship in UK Primary Care: Nested Cohort Study

    by Uy Hoang, Jessica Smylie, Elizabeth Button, Jack Macartney, Cecilia Okusi, Rachel Byford, Filipa Ferreira, Charis Xie, Mark Joy, Tristan Clark, et al.

    Background: Influenza and respiratory syncytial virus (RSV) predominantly circulate during the winter season and cause acute respiratory illness (ARI). Deploying molecular point-of-care testing (POCT) in primary care can inform whether a patient presenting with an ARI has influenza or RSV. An early virological diagnosis could facilitate appropriate use of antivirals and enable better antimicrobial stewardship. Objective: This study aimed to report the impact of POCT for influenza and RSV on antimicrobial prescribing, including antiviral therapy in primary care. Methods: The impact of POCT for influenza on antimicrobial stewardship (PIAMS) in UK primary care was a nested cohort study undertaken from January 20 to May 31, 2023, after the period of peak virus circulation, within practices that contribute data to the English sentinel network. People presenting with ARI had a nasopharyngeal swab performed and were tested for influenza and RSV with a molecular POCT analyzer located within the practice. Data on antimicrobial prescribing and other study outcomes were collected by linking information from the analyzer to coded data from the patient’s computerized medical record. Results: In total, 323 swabs were collected from 10 PIAMS study practices. In total, 59.7% (197/323) of swabbed patients were female, and the mean age was 37.28 (SD 25.05) years. Furthermore, 2.9% (9/323) of all swabs were positive, with 0.3% (1/323) positive for influenza A, 1.6% (5/323) positive for influenza B, and 0.9% (3/323) positive for RSV. In total, 80 patients were prescribed antibiotics 7 days following POCT testing. There were no instances of antiviral prescribing in the 7 days post testing. A statistically significant difference in antibiotic prescribing given a positive POCT result compared with a negative test was not found with an unadjusted odds ratio (OR) of 7 days post testing. A statistically significant difference in antibiotic prescribing given a positive POCT result compared with a negative test was not found with an unadjusted OR of 1.54 (95% CI 0.38‐6.30; P=.55) and adjusted OR of 1.21 (95% CI 0.00‐1.78). Conclusions: This study illustrates the risk of having a narrow study window; our observation period was not aligned with when influenza was circulating. The peak of weekly incidence of influenza in the sentinel network was in the last week of 2022, and RSV was circulating before this. Further evidence is needed to assess the impact of POCT on antimicrobial prescribing. The viruses tested for using POCT could be aligned with the circulating viruses identified by the sentinel network.

  • Open Access

    Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal (UNIVERSAL) study: a prospective observational cohort study protocol

    by Tommaso Morelli, Martha Purcell, Pedro Rodrigues, Charles Roberts, Olivia Cox, Paul H Lee, Kerensa Thorne, Alexander Allen, Angelica Cazaly, Jacqueline Nuttall, et al.

    Background: Respiratory viral infections (RVIs) are a significant cause of morbidity and hospital admission worldwide. However, the management of most viral infection-associated diseases remains primarily supportive. The recent COVID-19 pandemic has underscored the urgent need for a deeper understanding of RVIs to improve patient outcomes and develop effective treatment strategies. The Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal Study is an observational study which addresses this need by investigating the heterogeneity of RVIs in hospitalised adults, aiming to identify clinical and biological predictors of adverse outcomes. This study aims to bridge critical knowledge gaps in the clinical course and the economic impact of RVIs by characterising the phenotypic diversity of these infections and their recovery patterns following hospital admission and thus assisting with the optimal design of future interventional studies. Methods and analysis: This prospective longitudinal observational study (V.6, 20 September 2023) will be conducted across multiple UK secondary care sites from August 2022 onwards, with an aim to enrol 1000 participants testing positive for RVI. Adults admitted with respiratory symptoms who test positive for RVIs via the BioFire® FilmArray® System or other validated diagnostic PCR tests will be enrolled. The data collected include patient demographics, clinical history, comorbidities and symptoms experienced prior to, during and after hospitalisation with follow-up after discharge at weeks 1, 2, 4, 8, 12 and 26. In addition, biological samples are collected at multiple time points during the hospital stay. The primary endpoints are to study the impact of different RVIs and identify predictors of disease progression and length of stay. Secondary endpoints include time to recovery and healthcare cost. Exploratory endpoints focus on biomarker profiles associated with virus type and clinical outcomes. Ethics and dissemination: The study protocol received ethical approval from the relevant committees (English Ethics Reference Number: 22/WM/0119; Scottish Ethics Reference Number: 22-SS-0101, 20/09/2023). For patients who lack the capacity to consent, the study complies with the Mental Capacity Act 2005, using a consultee process where a family member, carer or an independent clinician may provide assent on behalf of the patient. Data from all the study centres will be analysed together and disseminated through peer-reviewed journals, conference presentations and workshops. The study group will ensure that participants and their families are informed of the study findings promptly and in an accessible format. Trial registration number: ISRCTN49183956 .


  • Open Access

    The impact of point of care testing for influenza on antimicrobial stewardship (PIAMS) in UK primary care: mixed methods study (Preprint)

    by Uy Hoang, Jessica Smylie, Elizabeth Button, Jack Macartney, Cecilia Okusi, Rachel Byford, Filipa Ferreira, Charis Xie, Mark Joy, Tristan Clark, et al.

    BACKGROUND Influenza and respiratory syncytial virus (RSV) predominantly circulate during the winter season and cause acute respiratory infections (ARI). Deploying molecular point-of-care testing (POCT) in primary care at can inform whether a patient presenting with an ARI has influenza or RSV. An early virological diagnosis, could facilitate appropriate use of antivirals and enable better antimicrobial stewardship. OBJECTIVE To report the impact of POCT for influenza and RSV on antimicrobial prescribing including antiviral therapy in primary care. METHODS The impact of POCT for influenza on antimicrobial stewardship (PIAMS) in UK primary care was an observational study undertaken 20th Jan–31st May 2023, in practices that contribute data to the English sentinel network. People presenting with ARI had nasopharyngeal swab performed and were tested for Influenza and RSV with a molecular POCT analyser located within the practice. Data on antimicrobial prescribing and other study outcomes were collected by linking information from the analyser to coded data from the patient’s computerised medical record (CMR). RESULTS In total 323 swabs were collected from ten PIAMS study practices. 59.7% (197/323) of swabbed patients were female, and the mean age was 37 years. 2.79% (9/323) of all swabs were positive, with 0.31% (1/323) positive for influenza A, 1.55% (5/323) postivie for influenza B and 0.93% (3/323) positive for RSV. In total 80 patients were prescribed antibiotics seven days following POCT testing. There were no instances of antiviral prescribing in the seven days post-testing. The odds ratio for antibiotic prescribing given a positive POCT result was 1.54 (95% CI: 0.38–6.30; P =0.55) compared with a negative test. CONCLUSIONS This study illustrates the risk of having a narrow study window, our observation period was not aligned with when influenza was circulating. The peak of weekly incidence of influenza in the sentinel network was in the last week of 2022, and RSV circulating prior to this. Further evidence is needed to assess the impact of POCT on antibimicrobial prescribing. The viruses tested for using POCT could be aligned with the circulating viruses identified by the sentinel network. CLINICALTRIAL Not applicable INTERNATIONAL REGISTERED REPORT RR2-10.2196/46938

  • Open Access

    Defining within-host SARS-CoV-2 RNA viral load kinetics during acute COVID-19 infection within different respiratory compartments and their respective associations with host infectiousness: a protocol for a systematic review and meta-analysis

    by Daniel Pan, Christopher A Martin, Joshua Nazareth, Shirley Sze, Amani Al-Oraibi, Mayuri Gogoi, Natalia Grolmusova, Pip Divall, Jonathan Decker, Eve Fletcher, et al.

    Introduction Understanding how RNA viral load changes (viral load kinetics) during acute infection in SARS-CoV-2 can help to identify when and which patients are most infectious. We seek to summarise existing data on the longitudinal RNA viral load kinetics of SARS-CoV-2 sampled from different parts of the respiratory tract (nose, nasopharynx, oropharynx, saliva and exhaled breath) and how this may vary with age, sex, ethnicity, immune status, disease severity, vaccination, treatment and virus variant. Methods and analysis We will conduct a systematic review and meta-analysis, using studies identified through MEDLINE and EMBASE (via Ovid). All research studies reporting primary data on longitudinal RNA viral load kinetics of infected patients with SARS-CoV-2 will be included. Methodological quality will be assessed using a validated checklist for longitudinal studies as well as predefined quality criteria for assessment of individual-level RNA viral load. Should the data allow, we will aim to perform individual patient-level meta-analysis. Our primary outcomes are duration to, and quantity of peak RNA viral load, and total duration of viral load shedding within different respiratory compartments. Secondary outcomes include duration of lateral flow antigen and virus culture positivity and variation of RNA viral load by age, immune status, disease severity, vaccination, treatment, lateral flow tests, viral culture positivity and SARS-CoV-2 variant. Study-level effects affecting observations, but not related to properties of the patient, such as the PCR platform and gene target will also be recorded. Random-effects models will estimate the population mean and individual-level variation in viral shedding conditional on the aforementioned variables. Finally, we will summarise the key mechanistic models used in the literature to reconstruct individual-level viral kinetics and estimate how different factors shape viral dynamics over time. Ethics and dissemination Ethical approval is not needed as data will be obtained from published articles or studies with data that have already received and ethical review for analysis. Manuscript(s) will be prepared for publication. Systematic review protocol registration PROSPERO ID: CRD42023385315


  • Open Access

    Comparison of two rapid host-response tests for distinguishing bacterial and viral infection in adults with acute respiratory infection

    by Bilge Eylem Dedeoglu, Alex R. Tanner, Nathan J. Brendish, Helen E. Moyses, Tristan W. Clark


  • Open Access

    Qualitative evaluation of a molecular point-of-care testing study for influenza in UK primary care

    by Charis Xuan Xie, Uy Hoang, Jessica Smylie, Carole Aspden, Elizabeth Button, Cecilia Okusi, Rachel Byford, Filipa Ferreira, Sneha Anand, Utkarsh Agrawal, et al.

    Background: Influenza contributes to the surge in winter infections and the consequent winter pressures on the health service. Molecular point-of-care testing (POCT) for influenza may improve patient management by providing rapid and accurate clinical diagnosis to inform the timely initiation of antiviral therapy and reduce unnecessary admissions and antibiotics use. Aim: To explore factors that influence the adoption or non-adoption of POCT in English general practices and provide insights to enable its integration into routine practice workflows. Design & setting: A qualitative implementation evaluation was conducted in 10 general practices within the English national sentinel network (Oxford RCGP Research and Surveillance Centre), from April–July 2023. Method: Using the Non-adoption, Abandonment, Scale-up, Spread, and Sustainability (NASSS) framework, data collection and analysis were conducted across 10 practices. We made ethnographic observations of the POCT workflow and surveyed the practice staff for their perspectives on POCT implementation. Data were analysed using a mix of descriptive statistics, graphical modelling techniques, and framework analysis. Results: Ethnographic observations identified the following two modes of POCT integration into practice workflow: (1) clinician POCT workflow, which typically involved batch testing owing to time constraints; and (2) research nurse or healthcare assistant POCT workflow, which was characterised by immediate testing of individual patients. Survey data indicated that most primary care staff considered the POCT training offered was sufficient and these practices were ready for change. Some participants agreed that there was the capacity and resources to integrate POCT into workflows. It was uncertain as to whether POCT required changes to organisational routines and processes. Conclusion: General practices should demonstrate flexibility in the workflow and workforce they deploy to integrate POCT into routine clinical workflow.


  • Open Access

    Evaluating the Impact of Diagnostic Stewardship in Community-Acquired Pneumonia with Syndromic Molecular Testing: A Randomized Clinical Trial

    by Dagfinn L. Markussen, Sondre Serigstad, Christian Ritz, Siri T Knoop, Marit H Ebbesen, Daniel Faurholt-Jepsen, Lars Heggelund, C. H. Henri van Werkhoven, Tristan W Clark, Rune O Bjørneklett, et al.

    Importance Lower respiratory tract infections, including community-acquired pneumonia (CAP), are a leading cause of hospital admissions and mortality. An aetiological diagnosis of CAP is delayed due to long turnaround times with laboratory testing. Rapid microbiologic diagnosis is imperative for the management of CAP and may limit antibiotic overuse. Molecular tests have the potential to optimize treatment decisions and management of CAP, but limited evidence exists to support their routine use. Objective To determine whether the use of a syndromic PCR-based panel for rapid testing of CAP in the emergency department (ED) leads to faster, more accurate microbiology-result-based treatment. Design, Setting, and Participants A pragmatic, parallel-arm, single-blinded, single-centre, randomised controlled superiority trial conducted in the emergency department of a large tertiary care Norwegian hospital, where adult patients with suspected CAP were recruited. Intervention Patients were randomly assigned 1:1 to rapid syndromic molecular panel testing (FAP-plus) of lower respiratory tract (LRT) samples and standard-of-care or standard-of-care alone. Main Outcomes and Measures Primary outcomes were the provision of pathogen-directed treatment based on a microbiological test result and the time to provision of pathogen-directed treatment (within 48h from randomisation). Results Between Sep 25, 2020, and Jun 21, 2022, 374 patients were enrolled, with 187 in each arm. Analysis of primary outcomes showed that 66 (35%) of 187 patients in the FAP-plus arm and 24 (13%) of 187 patients in the standard-of-care arm received pathogen-directed treatment corresponding to a reduction in absolute risk of 21.9% (95% CI 13.5–30.3%) and an OR for the FAP-plus arm of 3.53 (95% CI 2.13–6.02; pConclusions and Relevance The routine deployment of PCR testing for LRT-pathogens enables faster and more targeted microbial treatment for patients with suspected CAP. Rapid molecular testing could complement or replace selected standard time-consuming laboratory-based diagnostics. Trial registration ClinicalTrials.gov Identifier: NCT04660084 Question Does the judicious use of a syndromic PCR-based panel for rapid testing of patients hospitalised with suspected community-acquired pneumonia (CAP) lead to faster, more accurate microbiology-result-based treatment? Findings In this randomised controlled diagnostic stewardship trial, molecular testing significantly in-creased the proportion of suspected CAP patients that received pathogen-directed treatment and reduced the mean time to pathogen-directed treatment by 9.4h compared to standard-of-care. A syndromic PCR-based result was delivered within 4 hours for all CAP patients. Meaning The routine deployment of PCR testing for LRT-pathogens enables faster and targeted microbial treatment for patients with suspected CAP. Rapid molecular testing could complement or replace selected standard time-consuming laboratory-based diagnostics.

  • Open Access

    The Impact of Point-of-Care Testing for Influenza on Antimicrobial Stewardship (PIAMS) in UK Primary Care: Protocol for a Mixed Methods Study

    by Uy Hoang, Alice Williams, Jessica Smylie, Carole Aspden, Elizabeth Button, Jack Macartney, Cecilia Okusi, Rachel Byford, Filipa Ferreira, Meredith Leston, et al.

    Background: Molecular point-of-care testing (POCT) used in primary care can inform whether a patient presenting with an acute respiratory infection has influenza. A confirmed clinical diagnosis, particularly early in the disease, could inform better antimicrobial stewardship. Social distancing and lockdowns during the COVID-19 pandemic have disturbed previous patterns of influenza infections in 2021. However, data from samples taken in the last quarter of 2022 suggest that influenza represents 36% of sentinel network positive virology, compared with 24% for respiratory syncytial virus. Problems with integration into the clinical workflow is a known barrier to incorporating technology into routine care. Objective: This study aims to report the impact of POCT for influenza on antimicrobial prescribing in primary care. We will additionally describe severe outcomes of infection (hospitalization and mortality) and how POCT is integrated into primary care workflows. Methods: The impact of POCT for influenza on antimicrobial stewardship (PIAMS) in UK primary care is an observational study being conducted between December 2022 and May 2023 and involving 10 practices that contribute data to the English sentinel network. Up to 1000 people who present to participating practices with respiratory symptoms will be swabbed and tested with a rapid molecular POCT analyzer in the practice. Antimicrobial prescribing and other study outcomes will be collected by linking information from the POCT analyzer with data from the patient’s computerized medical record. We will collect data on how POCT is incorporated into practice using data flow diagrams, unified modeling language use case diagrams, and Business Process Modeling Notation. Results: We will present the crude and adjusted odds of antimicrobial prescribing (all antibiotics and antivirals) given a POCT diagnosis of influenza, stratifying by whether individuals have a respiratory or other relevant diagnosis (eg, bronchiectasis). We will also present the rates of hospital referrals and deaths related to influenza infection in PIAMS study practices compared with a set of matched practices in the sentinel network and the rest of the network. We will describe any difference in implementation models in terms of staff involved and workflow. Conclusions: This study will generate data on the impact of POCT testing for influenza in primary care as well as help to inform about the feasibility of incorporating POCT into primary care workflows. It will inform the design of future larger studies about the effectiveness and cost-effectiveness of POCT to improve antimicrobial stewardship and any impact on severe outcomes. International Registered Report Identifier (IRRID): DERR1-10.2196/46938